Edifoligide
Edifoligide is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure
Product Specifications
CAS Number
328538-04-1
Product Name Alternative
CGT 003
UNSPSC
12352208
Target
Early 2 Factor (E2F)
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Inflammation/Immunology
Smiles
[Edifoligide]
References & Citations
[1]Lopes RD, Williams JB, Mehta RH, et al. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012;164 (3) :379-386.e1.|[2]Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294 (19) :2446-2454.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682853-500 1x 500 µL
CD54 / ICAM-1 (15.2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040218-500 1x 500 µL
CD100 (Semaphorin-4D) (A8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472085-100 1x 100 µL
TLE1 (Synovial Sarcoma Marker) (TLE1/2085), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details